Hemostatic Technology Articles & Analysis
5 news found
EndoClot Plus, Inc. (EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot® Submucosal Injection Agent (EndoClot® SIA) manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China. This product is expected to be commercially available in the United States beginning in May 2020 and later this year in several international markets. EndoClot® ...
Endomedix, Inc., a developer of unique biosurgical products based on natural biopolymer systems, today announced it will provide the first public presentation of its work at a scientific meeting. The 2019 Annual Meeting is scheduled for April 3-6 in Seattle, Washington. The presentation will provide data and descriptions of the performance of its patented hydrogel biomaterial in a series of ...
Endomedix, Inc., a developer of unique biosurgical products based on its natural biopolymer systems, today announced that it has submitted a comprehensive patent application to protect both its latest chemistry technology and also the design and function of the spray-on hydrogel hemostat that it is developing for brain and spine surgery indications. This patent application further expands and ...
EndoClot Plus, Inc., a privately held medical device company founded by surgeons and biomaterial scientists announces the CE approval of EndoClot® Adhesive manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China. The product will be made available for discussion during the upcoming Digestive Disease Week held in Washington DC, June 2-5, 2018. EndoClot® Adhesive is a single-use ...
Endomedix, Inc. announced today that NIH has selected Endomedix to showcase its technology at the upcoming Biotechnology Industry Organization (BIO) annual meeting in Philadelphia, June 15-18, 2015. The National Institute for Neurological Disorders and Stroke is currently funding the Endomedix program to develop a surgical hemostat indicated for use in intracranial surgery through a multi-year ...